Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial-Reference-Cited by-同舟云学术

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

Published:2009-04 Issue:4 Volume:157 Page:599-605
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

James Stefan,Åkerblom Axel,Cannon Christopher P.,Emanuelsson Håkan,Husted Steen,Katus Hugo,Skene Allan,Steg Philippe Gabriel,Storey Robert F.,Harrington Robert,Becker Richard,Wallentin Lars

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes;Bassand;Eur Heart J,2007

2. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology;Silber;Eur Heart J,2005

3. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation;Sabatine;N Engl J Med,2005

4. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation;Yusuf;N Engl J Med,2001

5. Prasugrel achieves greater and faster P2Y12 receptor–mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease;Wallentin;Eur Heart J,2008

Cited by 341 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and Clinical Determinants of MACE and Haemorrhage in Antiplatelet Therapy: Insights from Pharmacogenomic Analysis;2024-09-12

2. The Impact of Sex on Antiplatelet and Anticoagulant Thromboprophylaxis in Patients with Peripheral Artery Disease Post-revascularization;Annals of Surgery;2024-06-11

3. Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention;Pharmacogenomics;2024-05-02

4. A novel LC-QTOF-MS/MS method for trace level identification and quantification of potential genotoxic impurity, 5-Nitro-2-(propylthio)pyrimidine-4,6-diol in ticagrelor drug substance;Analytical Chemistry Letters;2024-04-11

5. Comprehensive comparative efficacy and safety of potent P2Y12 inhibitors in patients undergoing coronary intervention: A systematic review and meta-analysis;IJC Heart & Vasculature;2024-04